Jan 28, 2013, 02.16 PM IST | Source: Moneycontrol.com

Glenmark gets US nod to market Mupirocin skin cream

Pharmaceutical company Glenmark's US subsidiary Glenmark Generics has received final approval from US Food and Drugs Administration for its abbreviated new drug application for Mupirocin Calcium Cream USP, 2 percent.

Moneycontrol Bureau

Pharmaceutical company Glenmark 's US subsidiary Glenmark Generics has received final approval from US Food and Drugs Administration for its abbreviated new drug application for Mupirocin Calcium Cream USP, 2 percent.

Mupirocin Calcium Cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length) caused by bacteria such as S aureus and S pyogenes, Glenmark said on Monday.

The cream had US sales of USD 56.5 million for the year-ended Sept 2012, it added, citing IMS Health data.

Glenmark now has 83 products authorized for distribution in the US and a further 46 ANDAs are pending approval with the FDA.

Glenmark shares hit a high of Rs 534.80 in morning trade on Monday and at 9:45 hrs, it was up 0.5 percent at Rs 517.35.

Also Read: Hexaware says not lost any clients; company on growth track  

Glenmark stock price

On July 01, 2015, Glenmark Pharma closed at Rs 1018.20, up Rs 24.70, or 2.49 percent. The 52-week high of the share was Rs 1021.40 and the 52-week low was Rs 532.00.


The company's trailing 12-month (TTM) EPS was at Rs 35.71 per share as per the quarter ended March 2015. The stock's price-to-earnings (P/E) ratio was 28.51. The latest book value of the company is Rs 103.03 per share. At current value, the price-to-book value of the company is 9.88.

Set email alert for

ADS BY GOOGLE

video of the day

Short-term players, beware of Greece: Religare Invesco MF

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.